ANKTIVA® + BCG
BCG-Unresponsive NMIBC CIS ± Papillary
Key Facts
About ImmunityBio
ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.
View full company profileAbout ImmunityBio
ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.
View full company profile